Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dodecane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.59 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 4/20 | 0.55 |
| ▸ | CES1 | P23141 | 4/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.52 |
| ▸ | FABP3 | P05413 | 4/20 | 0.50 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptanoate SCHEMBL6743537 | 0.87 | CA1 (0.73) | CA1CES2CES1GPR84FABP3 | |
| Octadecylamine SCHEMBL28997993 | 0.85 | DNM1 (0.59) | CA1CES2CES1 | |
| Propionic Acid SCHEMBL27963799 | 0.85 | DNM1 (0.59) | CA1CES2CES1 | |
| Dodecylamine SCHEMBL11763824 | 0.85 | DNM1 (0.59) | CA1CES2CES1 | |
| Dodecane SCHEMBL28245552 | 0.85 | CES2 (0.63) | CA1CES2CES1CA2GPR84 | |
| Propionic Acid SCHEMBL16799783 | 0.85 | FFAR3 (0.56) | CA1CA2FFAR3HDAC3HDAC1 | |
| Dodecanoate SCHEMBL11144164 | 0.84 | CA1 (0.76) | CA1CES2CES1GPR84FABP3 | |
| Propionic Acid SCHEMBL28516410 | 0.84 | SOAT1 (0.59) | CA1CES2CES1FABP3 | |
| Dodecane SCHEMBL28489607 | 0.84 | CA1 (0.48) | CA1CES2CES1CA2GPR84 | |
| Octane SCHEMBL28390058 | 0.82 | CES2 (0.60) | CA1CES2CES1CA2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| EP-1615935-A4 | PHOSPHATE DERIVATIVES | VITAL HEALTH SCIENCES PTY LTD (AU) | 2008-04-23 | — | — | EP | claimed |
| US-20070135390-A1 | Phosphate derivatives | VITAL HEALTH SCIENCES PTY. LTD (AU) | 2007-06-14 | — | — | US | claimed |
| JP-2006523622-A | — | — | 2006-10-19 | — | — | JP | claimed |
| EP-1615935-A1 | PHOSPHATE DERIVATIVES | Vital Health Sciences Pty Ltd. (AU) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092187-A1 | PHOSPHATE DERIVATIVES | VITAL HEALTH SCIENCES PTY LTD (AU) | 2004-10-28 | — | — | WO | claimed |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORP (US) | 2025-10-09 | — | — | US | disclosed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4288062-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | Epalex Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-11628178-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | disclosed |
| WO-2004091636-A1 | PHOSPHATE DERIVATIVES OF PHARMACEUTICAL PRODUCTS | VITAL HEALTH SCIENCES PTY LTD (AU) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092187-A1 | PHOSPHATE DERIVATIVES | VITAL HEALTH SCIENCES PTY LTD (AU) | 2004-10-28 | — | — | WO | disclosed |
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | BIOTIE THERAPIES GMBH (DE) | 2004-06-03 | — | — | US | disclosed |
| US-20040052754-A1 | Complexes of phosphate derivatives | VITAL HEALTH SCIENCES PTY LTD. (AU) | 2004-03-18 | — | — | US | disclosed |
| US-20030229139-A1 | Impregnating carrier with cyfluthrin; controlling particle size | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-11 | — | — | US | disclosed |
| US-6054459-A | INSECTICIDES AND ECTOPARASITICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| US-4728498-A | Process for disinfecting article with device dispensing chlorine donor and chlorine acceptor | ALZA CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628178-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | CA1 2700/4885CA2 2395/4885CES2 198/4885 |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | CA1 2700/4885CA2 2395/4885CES2 198/4885 |
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | PDE4A, PDE4B, PDE4C | CA1 3105/4885CA2 2211/4885CES2 258/4885 |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | CA1 2700/4885CA2 2395/4885CES2 198/4885 |
| US-20070135390-A1 | Phosphate derivatives | GNPAT, DERA, PGD | CA1 3772/4885CA2 1962/4885CES2 2200/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | CA1 2700/4885CA2 2395/4885CES2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.